Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 178

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 178
---
 value of the stock options on the grant date and therefore      
 does not affect our cash balance. The fair value of the stock options will likely vary from the actual value the holder receives           
 because the actual value depends on the number of options exercised and the market price of our Common Stock on the date of exercise       |

| (2) | Including $57,000 for                            
 Bernard’s role as Company’s VP head of strategy. |

| (3) | Mr. Jacobson resigned from                                      
 the Company’s board of directors effective as of June 30, 2025. |

| (4) | Mr. Flom resigned from                                             
 the Company’s board of directors effective as of December 1, 2024. |

Under the current Company’s policies, each director is to receive
cash compensation of $10,000 biannually, $1,000 per meeting or $300 for a virtual meeting.

Stock Plan

In March 2021, we adopted the Global Share Incentive
Plan (2021) (the “2021 Plan”), providing for the grant of non-qualified stock options and incentive stock options to purchase
shares of our common stock, restricted and unrestricted share awards and grant of restricted stock units, to the employees, services
providers, directors, officers, consultants and affiliates of the Company and its subsidiaries. The Plan, including the Appendix for
Israeli taxpayers was approved by our stockholders by written consent on March 10, 2021. We initially reserved 5,000,000 shares of our
Common Stock issuable under the 2021 Plan.

On November 11, 2024, following discussions with
the management of the Company, the Board has determined that it is advisable and in the best interests of the Company and its stockholders
to further amend the Plan, as amended (“Amendment #2”), to reduce the maximum number of shares reserved for issuance under
the Plan from 20,000,000 shares of Common Stock to 10,000,000 shares of Common Stock. Amendment No. 2 became effective on the date of
the approval by the Board of Directors, but it is subject to approval by the Company’s shareholders within 12 months, pursuant
to section 422(b)(1) of the Internal Revenue Code.

Outstanding Equity Awards at Fiscal Year End

The following table
sets forth certain information as of December 31, 2024 about our 2021 Plan under which our equity securities are authorized for issuance.

|